At present, many new ADC drugs (RC48-ADC, ARX788, etc.), BC vaccines (nelipepimut-S, GP2, etc.)and bispecific antibodies (KN026, ZW25, etc.)are being developed, hoping to bring new hope to patients with HER2-low BC [49–52]. Here, GP2 is linked to breast cancer.